MX2024004494A - Formulaciones de proteinas quimericas de factor viii y usos de las mismas. - Google Patents

Formulaciones de proteinas quimericas de factor viii y usos de las mismas.

Info

Publication number
MX2024004494A
MX2024004494A MX2024004494A MX2024004494A MX2024004494A MX 2024004494 A MX2024004494 A MX 2024004494A MX 2024004494 A MX2024004494 A MX 2024004494A MX 2024004494 A MX2024004494 A MX 2024004494A MX 2024004494 A MX2024004494 A MX 2024004494A
Authority
MX
Mexico
Prior art keywords
factor viii
formulations
chimeric proteins
viii chimeric
polypeptide
Prior art date
Application number
MX2024004494A
Other languages
English (en)
Spanish (es)
Inventor
Tyler Carlage
Randall Mauldin
Loubna Mzaalak Tazi
Timothy R Mccoy
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of MX2024004494A publication Critical patent/MX2024004494A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2024004494A 2021-10-15 2022-10-14 Formulaciones de proteinas quimericas de factor viii y usos de las mismas. MX2024004494A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163256432P 2021-10-15 2021-10-15
PCT/US2022/078097 WO2023064886A1 (en) 2021-10-15 2022-10-14 Formulations of factor viii chimeric proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2024004494A true MX2024004494A (es) 2024-07-15

Family

ID=84362012

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004494A MX2024004494A (es) 2021-10-15 2022-10-14 Formulaciones de proteinas quimericas de factor viii y usos de las mismas.

Country Status (12)

Country Link
US (1) US20240358800A1 (enExample)
EP (1) EP4415693B1 (enExample)
JP (1) JP2024538091A (enExample)
KR (1) KR20240082408A (enExample)
CN (1) CN118103034A (enExample)
AU (1) AU2022366974A1 (enExample)
CA (1) CA3229979A1 (enExample)
CO (1) CO2024004211A2 (enExample)
IL (1) IL311969A (enExample)
MX (1) MX2024004494A (enExample)
TW (1) TW202334244A (enExample)
WO (1) WO2023064886A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
PL3793588T3 (pl) * 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a

Also Published As

Publication number Publication date
EP4415693A1 (en) 2024-08-21
JP2024538091A (ja) 2024-10-18
CA3229979A1 (en) 2023-04-20
CN118103034A (zh) 2024-05-28
KR20240082408A (ko) 2024-06-10
EP4415693C0 (en) 2026-02-18
EP4415693B1 (en) 2026-02-18
US20240358800A1 (en) 2024-10-31
CO2024004211A2 (es) 2024-04-18
TW202334244A (zh) 2023-09-01
WO2023064886A1 (en) 2023-04-20
AU2022366974A1 (en) 2024-05-30
IL311969A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
MX2024015540A (es) Polipeptidos quimericos para usarse en el tratamiento de la hemofilia a
Fay et al. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity.
HRP20220960T1 (hr) Kimerni proteini faktora viii i njihova upotreba
WO2015023891A3 (en) Factor viii-xten fusions and uses thereof
MX9305729A (es) Formulas de proteinas de liberacion sostenida.
GB2467700A (en) Modified recombinant Factor VIII and von Willebrand Factor and methods of use
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
ATE549028T1 (de) Stabile analoga von glp-1
Gangadharan et al. The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells
DE69727149D1 (de) Varianten des vaskulären endothelzellwachsumsfaktors mit antagonistischer wirkung
ATE442373T1 (de) Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
DK0672138T3 (da) Kimære prokoagulante proteiner
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
DE69713112D1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
MX2023001262A (es) Polipéptidos inhibidores del ligando 1 de muerte programada que prolongan la vida media del suero.
ES2054365T3 (es) Inhibicion de la via de la regla del n final en celulas vivas.
YU394A (sh) Novi peptidi koji deluju kao antagonisti opijatskih receptora i postupci za njihovu izradu
MX2023015238A (es) Formulaciones de proteinas quimericas del factor viii y usos de las mismas.
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
MX2024013781A (es) Composición farmacéutica de la proteína de fusión del vegfr
EP1641824A4 (en) PEPTIDE ANALOGUES OF SUPERFAMILY OF RELAXINES
CO2023000048A2 (es) Conjugados de citoquina
ATE10364T1 (de) Retro-inverso analoga von c-terminalen pentaund hexapeptiden der verbindung p.
FR2841904B1 (fr) Analogues de facteurs x clivables par la thrombine